Kazia Therapeutics' paxalisib an Orphan Drug in U.S. for malignant glioma
Kazia Therapeutics' paxalisib an Orphan Drug in U.S. for malignant glioma
SeekingAlpha
0 shares
1 views
You might like
Related news coverage
Kazia Therapeutics directors show confidence in oncology strategy with on-market purchases
Proactive Investors
Kazia Therapeutics Ltd (ASX:KZA) directors Dr James Garner and Iain Ross have demonstrated their confidence in the company’s..
-
Kazia Therapeutics awarded US FDA Orphan Drug Designation to paxalisib treatment for malignant glioma
Proactive Investors
-
S&P/ASX 200 pares loss as Fortescue Metals' net profit surges 49% to a record US$4.7 billion
Proactive Investors
-
Kazia Therapeutics surges on grant of Rare Pediatric Disease Designation to paxalisib for DIPG
Proactive Investors
-
Kazia Therapeutics hits A$1 on grant of Rare Pediatric Disease Designation to paxalisib for DIPG
Proactive Investors